NEW YORK (GenomeWeb) – NeoGenomics today announced the closing of a public offering that raised $34.6 million in net proceeds.

The Ft. Myers, Fla.-based cancer genetic testing services firm offered 8.05 million shares at $4.60 per share, which included 1.05 million shares purchased by the underwriters on the offering as a result of the exercise of their overallotment option.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.